January 18, 2017
Ablynx issues additional common shares as result of warrant exercise
Ablynx has issued additional 154,342 common shares in exchange for EUR1,011,939.05 as the result of the exercise of warrants.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
January 18, 2017
Erytech to presents new preclinical data on ERY-MET at the 2017 ASCO GI Symposium
Erytech Pharma’s new data supporting the second company’s product candidate ERY-MET will be presented at the 2017 Gastrointestinal Cancers Symposium…
January 17, 2017
Sanofi’s new insuline combination of Saliqua cleared for Europe
The European Commission has cleared Sanofi’s Suliqua in combination with metformin, type 2 diabetes treatment, for European adult patients.
January 17, 2017
Biogen settles to pay Danish Forward $1.25 bilion
Danish biopharmaceutical company, Forward Pharma, has entered a deal with Biogen and certain other parties, regarding a Settlement and License Agreement.
January 17, 2017
BD Precise WTA kits for single cell research available for sale
Becton, Dickinson’s (BD’s) new kits that provide an easier method to identify and quantify genetic information in individual cells for genomics-based research, have started selling.
January 17, 2017
Allergan, Gedeon Richter report positive results from uterine fibroids drug trial
Allergan and Gedeon Richter have reported positive results from Venus II, the second of two pivotal phase III clinical trials…
January 17, 2017
Pharnext wins Best Life-Scineces IPO France 2016 Award
Pharnext, a French biopharmaceutical company focused on drugs against neurodegenerative diseases, has been named Best Life-Sciences IPO France 2016 Award.
January 17, 2017
Dechra’s acquisitions deliver good half year results
Dechra has issued an unaudited Trading Update covering the half year reporting period (the Period) from 1 July to 31…
January 17, 2017
Oxford Pharmascience studies/regulatory update for OXPzero, looks for potential partners
Oxford Pharmascience Group has completed laboratory work to identify modifications to the OXPzero technology platform that alter the release properties and enable faster release of the NSAID.
January 17, 2017
AstraZeneca tests overall and progression-free survivals in cancer related trials, focused on China
AstraZeneca has provided updates on some of its cancer related clinical trials including 1st-line non-small cell lung cancer (NSCLC). and a…